Excitatory amino acids (EAAs) are important mediators of ischemic injury in stroke. N.Methyl-D· aspartate (NMDA) receptor antagonists have been shown to be very effective neuroprotective agents in animal models of stroke, but may have unacceptable toxicity for human use. An alternative approach is to inhibit the re· lease of EAAs during stroke. BWI003C87 [5-(2,3,5trichlorophenyl)-2,4-diaminopyrimidine], a drug that in· hibits veratrine·induced release of the EAA glutamate in vitro, was tested in a rat model of proximal middle cere· bral artery (MCA) occlusion. BWlO03C87 significantly decreased ischemia· induced glutamate release in brain when given either 5 min before or 15 min following per-Brain injury following both focal and global isch· emia is mediated, at least in part, by glutamate or other endogenous excitatory amino acid (EAA) neurotransmitters gating a receptor·mediated neu· ronal calcium channel. Extracellular concentrations of the EAAs glutamate and aspartate are increased during ischemia due to both enhanced release of· EAAs from neurons and impaired reuptake (Ben· veniste et aI., 1984; Drejer et aI., 1985; Silverstein et aI., 1986). EAAs, acting pri marily via the N·methyl·D·aspartate (NMDA) re ceptor, increase intraneuronal calcium (MacDer mott et aI., 1986; Uematsu et aI., 1988) and are di-Abbreviations used: 2DG, 2-deoxyglucose; EAA, excitatory amino acid; GABA, -y-aminobutyric acid; HSP, heat shock pro tein; LCGU, local cerebral glucose utilization; MCA, middle ce rebral artery; NMDA, N-methyl-D-aspartate. 88 manent MCA occlusion. Pretreated and posttreated rats had smaller infarct volumes and preserved glucose me tabolism in the ischemic cortex at 24 h after MCA occlu· sion. BWI003C87 did not induce heat shock protein in the cingulate or retrosplenial cortex, suggesting that it does not injure neurons in these regions as do NMDA antago nists. These results demonstrate that drugs that inhibit glutamate release in ischemia may be nontoxic and show promise for the treatment of stroke.
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rectly toxic to neurons in vitro (Choi, 1987) . NMDA antagonists have been shown to be effective in ame liorating ischemic injury in animal models of stroke (Simon et aI., 1984; Gill et aI., 1987; Ozyurt et aI., 1988; Park et aI., 1988; Simon and Shiraishi, 1990) and are currently entering clinical trials. However, behavioral side effects and possible injury to neu rons in the cingulate gyrus and retrosplenial cortex produced by these drugs in rats have raised con cerns regarding their clinical utility (Olney et aI., 1989; Sharp et aI., 1991a) .
Another approach to limit excitotoxic injury in ischemia is to prevent the release of EAAs. BWI003C87 [5-(2,3,5-trichlorophenyl)-2,4-diamino pyrimidine] is structurally related to the antiepilep tic lamotrigine (Miller et aI., 1986) . Both these agents block glutamate release induced by the so dium channel agonist veratrine, but do not block glutamate release induced by depolarization with potassium Meldrum et aI., 1992) . Furthermore, lamotrigine has an anti epileptic profile in animal models similar to that of phenyt oin, which also acts at sodium channels (Leach et aI., 1986) . BWI003C87 is a more potent inhibitor of glutamate release in vitro than lamotrigine. BWI003C87 reduces ischemic injury when given prior to induction of global and focal cerebral isch emia (Meldrum et al., 1992) . This study aims to de termine if BWI003C87 is effective in inhibiting the release of EAAs during focal cerebral ischemia and to determine its effect upon brain infarction and glu cose metabolism when given after permanent mid dle cerebral artery (MCA) occlusion in the rat.
METHODS

Animal model
Focal cerebral ischemia was induced in isoflurane anesthetized rats by occlusion of the MCA, using the technique of Shiraishi et al. (1989) . Male Sprague-Dawley rats (275-300 g) were induced with 5% isoflurane, intu bated, and ventilated with 1. 5% isoflurane. The femoral artery and vein were cannulated. Animals were main tained on a heating pad and under a heating lamp; con tralateral temporalis muscle temperature, rectal temper ature, arterial blood gases, and blood pressure were mon itored. An incision was made over the temporal scalp, the temporalis muscle was retracted, and a portion of the maxilla was removed to expose the foramen ovale. The foramen ovale was enlarged to expose the origin of the MCA. The MCA was then coagulated under direct vision from its origin to the olfactory tract. Care was taken to coagulate the penetrating arteries that arise from the MCA and supply the lateral caudate at this level.
Our previous experiments have shown that BWlO03C87 has maximal effect in focal ischemia with 20 mg/kg i. v. dosing (Meldrum et aI. , 1992) . In the current study, this dose was given either 5 min before or 15 min after MCA occlusion. An equal volume of saline was in fused intravenously to control animals at corresponding times. A sham operation group consisted of four rats sub jected to the identical surgical procedures except that the MCA was not occluded.
Extracellular amino acids
Microdialysis was used to determine changes in extra cellular EAAs after MCA occlusion in 30 rats. One hour prior to MCA occlusion, animals were placed in a Kopf stereotaxic frame. Two-millimeter microdialysis probes (Carnegie Medicin, Stockholm, Sweden) were inserted into the ipsilateral caudate (anteroposterior bregma + 0.3, lateral 4. 0, depth 5. 0 mm) and rostral frontal cortex (an teroposterior bregma -0.3, lateral 4. 0, depth 2. 0 mm). These probe positions correspond to the core and pen umbra of the eventual infarction as determined by local cerebral glucose utilization (LCG U) measurements 1 h after MCA occlusion (see Fig. 3A , page 94). At 1 h after MCA occlusion, the lateral caudate (probe site 1) has already become severely hypometabolic. The rostral cor tex (probe site 2) has increased glucose utilization at this time. We have previously shown that glucose utilization is lost in the rostral cortex by 4 h (Shiraishi et aI. , 1989) . Probes were perfused with artificial CSF at 1 fLl/min via a Carnegie Medicin CMA-I00 microinjection pump (Wages et aI. , 1986) . This formulation of artificial CSF is pH 7. 4 in room air and is not aerated with 5% CO2, Two baseline samples were collected 20 min before MCA occlusion. Samples were then obtained hourly after MCA occlusion for 4 h. We have previously shown that microdialysate glutamate peaks at 60 min in cortex when samples are collected at 10-or 20-min intervals (Graham et aI. , 1990a (Graham et aI. , , 1991 . Dialysate amino acid content was determined by reverse-phase HPLC with electrochemical detection (Graham et aI. , 1990a) . Peak areas were determined by a blinded observer using Nelson Analytical Software.
Microdialysis experiments were randomized in two groups. In the first group, rats (n = 14) were given drug or saline 5 min before MCA occlusion. Four additional rats were given saline prior to sham operation. In the second group, rats (n = 12) were given BWI003C87 or saline 15 min after MCA occlusion.
Infarct size
Infarct size was determined in an additional 24 rats given either saline or drug 5 min prior to or 15 min after MCA occlusion. Animals were euthanized with pentobar bital at 24 h after MCA occlusion. Brains were coronally sectioned every 400 mm from the anterior limit of the caudate to the posterior hippocampus. Sections were stained with cresyl violet for computerized image analysis of infarct size. The total volume of the infarction was determined by a blinded observer analyzing 22-25 sec tions using a computerized image analysis system (MCID, St. Catherine, Ontario, Canada). The area of in farction of each section was first determined by measur ing the area of normally staining brain in the hemispheres ipsilateral and contralateral to the MCA occlusion. Area of infarction was then determined by the following equa tion:
This technique negates the effect of edema upon infarct size (Swanson et aI. , 1989) . The volume of infarction was calculated by summing the infarct area in each section measured and multiplying by the distance between sec tions. A comparison of the effect of drug in sparing cortex versus basal ganglia was determined in one section through midcaudate by measuring the areas of basal gan glia and cortex in each hemisphere. This section is through the region of maximum infarction in this model.
LCGU
LCGU was determined 24 h after MCA occlusion in the same rats used for histological determination of infarct size.
[14C]2-Deoxyglucose ([14C]2DG) (150 mCi/ 100 g) was injected intravenously and -100 fLl of blood was ob tained at 0, 15, and 30 s and at 1,3,5,7, 10, 15,20,25, and 30 min for [14C]2DG and blood glucose determinations. The brains were removed 30 min later and rapidly frozen in -30°C 2-methylbutane. Sections were obtained for au toradiography, as described previously, and analyzed with a computerized image analysis system (Sharp et al. , 1988) . LCGU was calculated using the method of Sokoloff et al. (1977) . Rate constants used in the calcu lation of LCGU may be altered in ischemia; however, we have previously shown that similar results for LCGU are obtained using other proposed methods of LCGU calcu lation in this model (Shiraishi et aI. , 1989) . The boxes in Fig. 3B -D correspond to regions sampled in the ipsilat eral hemisphere for LCGU. These areas also correspond to the position of the microdialysis probes ( Fig. 3A ).
Heat shock protein immunohistochemistry
To determine if BWlO03C87 damages neurons in the cingulate gyrus and retrosplenial cortex as do NMDA an tagonists, awake rats (n = 9) were injected with either I mg/kg i.p. MK-801, 20 mg/kg i. p. BWI003C87, or equal volume of saline. The behavior of rats given intraperito neal BWlO03C87, MK-80 1, or saline was observed for 6-8 h after injection. Twenty-four hours later the rats were anesthetized with pentobarbital and perfused with 100 ml of 0.9% saline followed by 500 ml of 4% paraform aldehyde in 0. 1 M phosphate buffer (pH 7.4), and their brains were removed. Coronal sections, 100 J.1m thick, were cut on a vibratome and reacted histochemically with a monoclonal antibody to the 72-kDa heat shock protein (HSP72; Amersham) and the avidin-biotin-peroxidase method as described previously (Sharp et aI. , 1991b) .
Statistical analysis
The statistical significance of differences between groups was determined with analysis of variance. Post hoc testing was performed using the Newman-Keuls test. p < 0.05 was used as the acceptable level of confidence.
RESULTS
Physiologic variables
There was no significant difference between tem poralis muscle temperature, blood glucose, or blood gases in saline-treated, drug-treated, or sham operated groups. BWI003C87 often produced a transient drop in blood pressure of 10-20 mm Hg that lasted, at most, a few minutes. However, 5 min after drug or saline infusion, there were no signifi cant differences in any physiologic variables be tween groups.
Extracellular amino acid concentrations
The effect of BWlO03C87 upon glutamate release is shown in Fig. I . Extracellular glutamate concen trations peak at 1-2 h after MCA occlusion in the cortex (the metabolic penumbra), then return to near baseline by 4 h. In the caudate (the ischemic core of the infarction), glutamate peaks at 2-3 h after MCA occlusion and remains elevated at high levels throughout the experiment. Glutamate re lease was effectively diminished in the cortex when BWlO03C87 was given both before and after MCA occlusion. In the caudate, pretreatment with drug significantly decreased peak glutamate concentra tions in dialysate of both caudate and cortex com pared with pretreatment controls. Posttreatment with BWlO03C87 was only marginally effective in lessening glutamate release in the caudate, which was significantly reduced only at I h after MCA occlusion. BWI003C87 administration also de creased release of other neurotransmitter amino ac ids, although to a lesser extent than glutamate (Ta ble 1). Drug-treated animals had significantly less -y-aminobutyric acid (GABA) release, but changes J Cereb Blood Flow Metab. Vol. 13. No.1. 1993 in aspartate and glycine did not reach statistical sig nificance. The peak excitotoxic index, proposed by Globus et al. (199 1) to reflect the cumulative effects of glutamate, glycine, and GABA, was not signifi cantly changed by either pre-or posttreatment with BWI003C87.
Infarct size
Total infarct volume was significantly decreased in animals treated both 5 min before and 15 min after MCA occlusion ( Fig. 2A ). Pretreatment ap pears to be slightly more effective, but the differ ence is not significant. Figure 2B illustrates the ef fect of the drug upon sparing of cortex versus cau date in the section through the maximal infarct region. The drug was effective in sparing cortex in both pretreated and posttreated animals, but BWI003C87 did not significantly protect caudate. Figure 2C summarizes the effect of drug upon in farction at each section measured. There is a more striking protective effect in the anterior sections than in posterior sections where the infarct is lim ited to the olfactory cortex, an area directly adja cent to the MCA. Although there are significant dif ferences among groups at many single sections, post hoc correction for multiple comparisons does not allow one to conclude that iadividual sections are significantly different.
Local cerebral glucose metabolism
The preservation of glucose metabolism by BWlO03C87 also demonstrates its protective effect in focal ischemia. Representative autoradiographs of sections through the largest area of infarction are shown in Fig. 3A -D. LCGU in regions of cortex and caudate corresponding to the probe positions is summarized in Fig. 3E . LCGU in the cortical pen umbra was preserved by both pre-and posttreat ment as compared with saline controls, but there was no preservation of LCG U in the caudate. Figure 4 shows the effect of BWlO03C87 and MK-80 1 upon induction of HSP72 in the cingulate gyrus. MK-80 1 at I mg/kg i.p., a dose that has been shown to be effective in attenuating focal cerebral ischemic injury, induces HSP72 immunoreactivity in neurons in layers 3 and 4 of the cingulate (Fig. 4 ) and in the retrosplenial cortex (not shown). The therapeutic dose of BWI003C87 (20 mg/kg i.v.) or saline did not induce HSP72 immunoreactivity in the posterior cingulate, retrosplenial cortex, or any other brain region (Fig. 4C ). Animals given BWI003C87 became sedated but did not exhibit any of the other abnormal behaviors observed in ani mals given MK-80 1. 
HSP immunohistochemistry
DISCUSSION
These experiments utilized a rodent model of stroke and studied the effects of pharmacologic in hibition of sodium channel function on ischemia induced glutamate release, infarct volume, and glu cose metabolism. We hypothesized that sodium channel blockade would attenuate the increased glutamate concentration in the region of focal isch emia (by decreasing depolarization-induced gluta mate release) and thereby lessen infarct size and preserve glucose metabolism. The results are con sistent with this hypothesis. Treatment with the so dium channel antagonist BWI003C87 reduced in farct size in the cortex but not in the ischemic core (caudate nucleus). Treatment 5 min before or 15 min after permanent MCA occlusion was equally effective (Fig. 2) . Glucose metabolism measured 24 h after permanent MCA occlusion was preserved in protected cortex (Fig. 3) .
Ischemia-induced glutamate release in the cortex was also attenuated with BW1003C87 administered 5 min before or 15 min after MCA occlusion (Fig.  1 ). Pretreatment only also reduced microdialysate glutamate in the caudate, but these glutamate con centrations were greater than in microdialysate from infarcting cortex in saline-treated animals. The different results in cortex and caudate are explained mainly by the availability of collateral circulation. The lateral caudate is supplied exclusively by pen etrating end arteries from the MCA; thus, it has poor collateral blood flow. This region loses its glu cose utilization first after proximal MCA occlusion (Shiraishi et aI., 1989) . Therefore, the lateral cau date is the core of the ischemic region. The cortex with substantial collaterals forms the' 'penumbra. "
J Cereb Blood Flow Metab, Vol. 13, No.1, 1993 Two major mechanisms have been proposed to explain glutamate release during cerebral ischemia: (a) synaptic release of neurotransmitter stores of glutamate (Drejer et aI., 1985) ; (b) leakage of cyto solie stores of glutamate by reversal of the Na + I glutamate transporter (Butcher et aI., 1987; Sanchez-Prieto et aI., 1987; Ikeda et aI., 1989) . Un der normal conditions, the Na + Iglutamate trans porter is the primary mechanism for glutamate re uptake by neurons, but during depolarization and entry of Na + into the neuron it can export gluta mate into the extracellular space (Nicholls et aI., 1987) . The relative contribution of these two mechanisms to glutamate release in ischemia re mains controversial. BWI003C87 could counter both mechanisms of glutamate release. Since BW1003C87 acts at the Na + channel, it may de prive the cell of cytosolic Na + necessary for rever sal of the Na + Iglutamate transporter. It may also act to prevent depolarization and synaptic release of glutamate. Benveniste et al. (1989) showed that removing the excitatory input from CAl prevented the majority of glutamate release during the initial 10 min of global ischemia. Thus, cell depolarization is necessary for glutamate release, either through synaptic release or reversal of the Na + Iglutamate transporter, at least within the initial phase of isch emia.
A third possible mechanism of glutamate release is the leakage of glutamate from damaged plasma membranes. Leakage of glutamate through dam aged membranes could be one explanation why di alysate glutamate remains elevated in the core of the infarction, hours after MCA occlusion. How ever, the lack of glutamate elevation in the rostral cortex after 2 h even though this region infarcts in control animals suggests that such nonspecific leak age of glutamate from dying neurons plays a minor role in glutamate release, at least in the cortex. Moreover, pretreatment with BWlO03C87 de creased glutamate release in caudate, even though this region infarcts. These observations suggest that BWI003C87's effect on microdialysate glutamate is distinct from its neuroprotective effect. Other factors besides glutamate release also de termine its dialysate concentration. Removal of glu tamate from the extracellular space by either re uptake into neurons or glia or diffusion into sur rounding tissue or the circulation also determines its extracellular concentration. BWI003C87 may preserve glutamate reuptake by the same mecha-nism by which it decreases glutamate release: pres ervation of the normal sodium gradient. The so dium/glutamate cotransporter is a primary means by which glutamate reuptake occurs (Kauppinen et a!., 1988) . Another means by which BWI003C87 might affect microdialysate glutamate concentra tions is by its effects on diffusion. Benveniste (1989) has shown that dialysate concentrations are depen dent upon the tortuosity coefficient of the extracel lular space. With necrosis, there could be less tor tuosity of the extracellular space and thus freer dif fusion of glutamate into the microdialysis probe, potentially producing an artifactual elevation in ex tracellular glutamate. BWI003C87's effect on dial ysate glutamate may not easily be explained by this
effect. The drug decreased dialysate glutamate in the caudate when given prior to the onset of isch emia, even though it did not prevent development of infarction in this region.
Agents such as BWlO03C87, which act presynap tically to prevent neuronal depolarization, would be expected to decrease release of all neurotransmit ters. Indeed, GABA, glycine, and aspartate were all reduced to some extent in this study. Globus et al. (1991) have proposed that it is the sum of changes in the extracellular excitatory transmitters glutamate and glycine, contrasted with changes in the inhibi tory transmitter GABA, that determines the extent of ischemic injury. However, this proposed "exci totoxic index" (glutamate x glycine/GABA) is not significantly decreased by BWlO03C87 (Table 1) yet there is significant reduction of ischemic injury. This observation is in keeping with a principal role for glutamate in the pathogenesis of excitotoxic in jury in ischemia and a direct effect of this drug upon extracellular glutamate concentrations. Inhibition of glutamate release will not block the effects of EAAs that have already been released into the extracellular space. Drugs that inhibit glu tamate release, therefore, might be argued to be effective only with administration prior to the onset of ischemia. However, extracellular glutamate re quires 1-2 h to reach peak concentrations after MeA occlusion in the ischemic cortex; thus, re lease continues for at least this period. The attenu ation of infarct size in these studies was not differ ent with pretreatment versus 15-min delayed treat ment, supporting postischemia efficacy.
Elevations in extracellular glutamate may not be the only means by which excitotoxicity occurs in cerebral ischemia. Normally functioning astrocytes are very efficient at removing glutamate from the extracellular space (Yu et aI., 1986) , so that synap tically released glutamate may not result in in creased extracellular glutamate in normal brain. Ac cordingly, excessive synaptic release of glutamate could occur and produce excitotoxicity without an increase in extracellular glutamate concentrations detectable by microdialysis. There is evidence that increased glutamate release occurs during seizures (Leach et aI., 1985) , but changes in dialysate gluta mate do not occur in kainate-induced status (Leh mann et aI., 1985) . In global ischemia, neurons are selectively injured but glia survive; therefore, glu tamate released during global ischemia may be taken up by the still viable glia and not result in increased extracellular glutamate. Excessive synap tically released glutamate that does not result in in creased microdialysate glutamate could explain why non-NMDA EAA antagonists are effective 1 h after global ischemia (Diemer et aI., 1990; Shear down et aI., 1990) , at a time when extracellular glu tamate concentrations have normalized (Benveniste et aI., 1984) . Therefore, drugs that inhibit glutamate release could be effective for longer intervals than suggested by the microdialysis data alone.
HSP72 is not found in normal rat brain, but is induced in response to neural injury (Welch et ai. 1986; Brown et aI., 1989; Gonzalez et aI., 1989) . HSP72 is thought to be induced by denatured pro teins and may serve an important repair function in injured cells (Welch et aI., 1986; Brown et aI., 1989) . Sharp et ai. (l991a) have shown that HSP72 is induced in neurons of the posterior cingulate and retrosplenial cortex in normal rats given MK-801 and phencyclidine. The HSP72-containing neurons also contain cytoplasmic vacuoles (Olney et aI., 1991; Sharp et aI., 1991a) . These vacuoles were first described by Olney et ai. (1989) as evidence that NMDA antagonists damage this population of neu rons. Concern that NMDA antagonists may damage normal neurons has tempered the enthusiasm for their human use; our MK-801lHSP72 data confirm the cytotoxicity of MK-801. However, the dose of BWI003C87 that is maximally effective in stroke does not induce HSP72 anywhere in the brain. Therefore, presynaptic glutamate release inhibitors may not share this toxicity with NMDA antago nists.
EAA release during cerebral ischemia may be de creased by several other approaches. Adenosine analogues that block presynaptic A 1 receptors de creased neurotransmitter release and have been re ported to decrease ischemic injury (Evans et aI., 1987; DeLeo et aI., 1988; von Lubitz et aI., 1988) . Hypothermia decreases glutamate release and the extent of ischemic damage (Busto et aI., 1989; Morikawa et aI., 1992) . Several other drugs that have been shown to be neuroprotective may also act by decreasing glutamate release. Opioid antag onists inhibit glutamate release in global ischemia (Graham et aI., 1990b) and may be neuroprotective (Faden et aI., 1990) . Methionine sulfoximine, an in hibitor of glia glutamine synthetase, which depletes brain glutamine stores and decreases K + -evoked glutamate release, decreases infarct size in rat focal ischemia (Paulsen and Fonnum, 1989; Swanson et aI., 1990) . These studies support the hypothesis that inhibition of EAA release during ischemia is an ef fective strategy for reducing ischemic injury.
Pharmacologic inhibition of glutamate release may have several advantages for neuroprotection over drugs that block postsynaptic EAA receptors. Since release inhibitor drugs do not act at the NMDA receptor, they avoid the phencyclidine-like behavioral side effects and vacuolar damage. Fur thermore, non-NMDA EAA receptors may also play a role in mediating excitotoxic injury in isch emia. Non-NMDA antagonists are neuroprotective in global ischemia and may be synergistic to NMDA antagonists in ameliorating glutamate toxicity in vitro (Sheardown et aI., 1990; Kaku et aI., 1991) . Inhibition of glutamate release prevents activation of both NMDA and non-NMDA receptors and thus could be more effective than NMDA antagonism alone.
BWI003C87 inhibits glutamate release in isch emia, decreases infarct size, and preserves glucose metabolism in ischemic cortex when given either before or after rat MCA occlusion. This drug is po tent in decreasing infarct size in this model of stroke, yet does not produce the injury to the cin gulate gyrus and retrosplenial cortex that occurs with NMDA antagonists. It, like lamotrigine, has antifolate activity, so BWlO03C87's clinical utility may be limited (Meldrum et aI., 1992) . Further stud ies are required to compare the efficacy of these agents with that of NMDA antagonists and to de termine if glutamate release inhibitors are effective when administered at greater intervals after isch emia. These data suggest that drugs that inhibit glu tamate release may have great promise in the treat ment of stroke.
